2-(4-bromo-phenyl)-1(9)H-benzo[d]imidazo[1,2-a]imidazole | CAS:30513-47-4

We serve 2-(4-bromo-phenyl)-1(9)H-benzo[d]imidazo[1,2-a]imidazole CAS:30513-47-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
2-(4-bromo-phenyl)-1(9)H-benzo[d]imidazo[1,2-a]imidazole

Chemical Name:2-(4-bromo-phenyl)-1(9)H-benzo[d]imidazo[1,2-a]imidazole
CAS.NO:30513-47-4
Synonyms:2-(4-bromophenyl)-9H-Imidazo[1,2-a]benzimidazole
Molecular Formula:C15H10BrN3
Molecular Weight:312.16400
 
Specification:
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:OLED intermediates



Contact us for information like 2-(4-bromo-phenyl)-1(9)H-benzo[d]imidazo[1,2-a]imidazole chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-(4-bromophenyl)-9H-Imidazo[1,2-a]benzimidazole physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-(4-bromo-phenyl)-1(9)H-benzo[d]imidazo[1,2-a]imidazole Use and application,2-(4-bromophenyl)-9H-Imidazo[1,2-a]benzimidazole technical grade,usp/ep/jp grade.


Related News: Active pharmaceutical ingredients or APIs can be defined as the chemicals used to manufacture pharmaceutical drugs.exo-3,6-Methylene-1,2,3,6-tetrahydrophthalic anhydride manufacturer Active pharmaceutical ingredients or APIs can be defined as the chemicals used to manufacture pharmaceutical drugs.Chloroiodomethane supplier A number of UK citizens who failed to leave the coronavirus-struck Chinese city of Wuhan last week are now on a second flight to Europe, UK Foreign Secretary Dominic Raab said Sunday.N,N'-(4,6-Dichloropyrimidine-2,5-diyl)diformamide vendor A number of UK citizens who failed to leave the coronavirus-struck Chinese city of Wuhan last week are now on a second flight to Europe, UK Foreign Secretary Dominic Raab said Sunday.In the context of increasingly tight global productive capacity cooperation in the pharmaceutical industry, some multinational pharmaceutical companies have chosen to abandon their original full industrial chain model and shift their focus to market operations. R & D, clinical, and production links reduce costs through outsourcing. Patented APIs came into being.